The FDA’s earlier-than-expected approval of Janssen's and Pharmacyclics' Imbruvica (ibrutinib) may be a sign the breakthrough therapy designation is doing its job of expediting the pathway for medicines from development to the marketplace.
The drug is only the second with the status to gain the agency's blessing, following Genentech's and Roche's Gazyva (obinutuzumab/GA101),...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

